Malignant Solid Tumor

Oncology·MeSH: Congenital Abnormalities

20 drugs in development·6 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
investigator's choice chemotherapy	Genmab A/S (GMAB)
tak-505	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
tak-505	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
zl-1218	Zai Lab Ltd (ZLAB)

Phase 1(7)

Drug	Company
5-FU	BioNTech SE (BNTX)
BNT314	BioNTech SE (BNTX)
gen1042	Genmab A/S (GMAB)
GEN1042	BioNTech SE (BNTX)
GEN1055	BioNTech SE (BNTX)
gen1057	Genmab A/S (GMAB)
premedication	Genmab A/S (GMAB)

Phase 1/Phase 2(9)

Drug	Company
5-fu	GENMAB A/S (GNMSF)
5-fu	Genmab A/S (GMAB)
gen1042	Genmab A/S (GMAB)
gen1055	Genmab A/S (GMAB)
gen1055	GENMAB A/S (GNMSF)
gen1057	GENMAB A/S (GNMSF)
gen1078	Genmab A/S (GMAB)
gen1078	GENMAB A/S (GNMSF)
standard chemotherapy	Genmab A/S (GMAB)

Compare drugs

investigator's choice chemotherapy vs tak-505 investigator's choice chemotherapy vs zl-1218 investigator's choice chemotherapy vs 5-FU

Frequently asked questions

How many drugs are in development for Malignant Solid Tumor?

BioSniper tracks 20 drugs in development for Malignant Solid Tumor across 6 companies.

How many clinical trials target Malignant Solid Tumor?

There are 7 clinical trials targeting Malignant Solid Tumor tracked by BioSniper.

Deep-dive into Malignant Solid Tumor

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis

Malignant Solid Tumor — Drugs in Development & Clinical Trials | BioSniper